SAN DIEGO, Jan. 30, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it has expanded a successful pilot study and entered into a research collaboration with the University of Nebraska Medical Center (UNMC). Dr. Kausttubh Datta, Professor of Biochemistry and Molecular Biology at UNMC, will serve as the investigator for the research collaboration. Dr. Datta is an expert in the field of neuropilin-2 (NRP-2) biology and conducts research related to molecular mechanisms of cancer progression and metastasis.
an assessment of the impact of different anti-NRP-2 domain-specific antibodies in immunology and cancer biology.